Multiple Myeloma Treatment Paradigm Improved Markedly In Recent Years
Kenneth C. Anderson, MD, discusses how he has seen the treatment paradigm transform over the last decade in multiple myeloma.
Kenneth C. Anderson, MD, Kraft Family Professor of Medicine at Harvard Medical School and program director of Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute, discusses how he has seen the treatment paradigm transform over the last decade in multiple myeloma.
Some of these new agents that have become available for the treatment of patients with multiple myeloma include immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, among other novel therapies. These agents are often used in combination, in triplet regimens, and now quadruplets, Anderson says.
The outlook for patients with multiple myeloma has markedly improved, and many patients now have multiple myeloma as a chronic illness as a consequence to these new advances in treatment. There are about 27 therapies that have received approval from the FDA over the last 10 to 15 years, Anderson says. With these treatments, patients have better outcomes due to all the progress in the field.
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
